These numerous changes result in hyperkeratosis, follicular plugging, and inflammation which then manifest as a papulopustular rash which is a common and well-established side effect of HER1/EGFR inhibitor treatments as it is reported to occur at some point during therapy in 60–90% of treated patients (38). This evidence concerns the gene EGFR and Hyperkeratosis.